Oramed Pharmaceuticals Stock Performance
| ORMP Stock | USD 2.37 0.02 0.85% |
The company holds a Beta of 0.0651, which implies not very significant fluctuations relative to the market. As returns on the market increase, Oramed Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oramed Pharmaceuticals is expected to be smaller as well. Oramed Pharmaceuticals right now holds a risk of 2.33%. Please check Oramed Pharmaceuticals skewness, and the relationship between the total risk alpha and day median price , to decide if Oramed Pharmaceuticals will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Oramed Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable primary indicators, Oramed Pharmaceuticals is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Actual Historical Performance (%)
One Day Return 0.63 | Five Day Return 3.25 | Year To Date Return (2.65) | Ten Year Return (60.25) | All Time Return (80.12) |
Last Split Factor 1:12 | Last Split Date 2013-01-23 |
1 | ORMP - Oramed Pharmaceuticals Inc. Latest Stock News Market Updates - StockTitan | 10/07/2024 |
2 | Scilex Holdings CEO Jaisim Shah purchases 29,751 in common stock | 10/17/2024 |
3 | Scilex director Chun Jay acquires 4,750 in common stock | 10/18/2024 |
4 | Scilex executive chairperson Ji Henry buys 8,351 in stock | 10/31/2024 |
5 | Acquisition by Joshua Hexter of 30000 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | 11/07/2024 |
6 | Oramed Pharmaceuticals Share Price Passes Below 200-Day Moving Average - Should You Sell - MarketBeat | 11/20/2024 |
| Begin Period Cash Flow | 40.5 M |
Oramed |
Oramed Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 240.00 in Oramed Pharmaceuticals on August 29, 2024 and sell it today you would lose (3.00) from holding Oramed Pharmaceuticals or give up 1.25% of portfolio value over 90 days. Oramed Pharmaceuticals is currently generating 0.007% in daily expected returns and assumes 2.3268% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Oramed, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oramed Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oramed Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oramed Pharmaceuticals, and traders can use it to determine the average amount a Oramed Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.003
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ORMP |
Estimated Market Risk
| 2.33 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Oramed Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oramed Pharmaceuticals by adding Oramed Pharmaceuticals to a well-diversified portfolio.
Oramed Pharmaceuticals Fundamentals Growth
Oramed Stock prices reflect investors' perceptions of the future prospects and financial health of Oramed Pharmaceuticals, and Oramed Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oramed Stock performance.
| Return On Equity | 0.0289 | ||||
| Return On Asset | -0.0412 | ||||
| Current Valuation | (47.14 M) | ||||
| Shares Outstanding | 40.77 M | ||||
| Price To Earning | (11.22) X | ||||
| Price To Book | 0.61 X | ||||
| Price To Sales | 141.54 X | ||||
| Revenue | 1.34 M | ||||
| Gross Profit | 2.7 M | ||||
| EBITDA | (12.85 M) | ||||
| Net Income | 5.53 M | ||||
| Cash And Equivalents | 133.91 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 51.01 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.01 X | ||||
| Book Value Per Share | 3.89 X | ||||
| Cash Flow From Operations | (10.29 M) | ||||
| Earnings Per Share | 0.51 X | ||||
| Market Capitalization | 94.58 M | ||||
| Total Asset | 220.55 M | ||||
| Retained Earnings | (157.56 M) | ||||
| Working Capital | 109.37 M | ||||
| Current Asset | 31 M | ||||
| Current Liabilities | 4 M | ||||
About Oramed Pharmaceuticals Performance
Assessing Oramed Pharmaceuticals' fundamental ratios provides investors with valuable insights into Oramed Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Oramed Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.23) | (0.25) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.22) | (0.24) |
Things to note about Oramed Pharmaceuticals performance evaluation
Checking the ongoing alerts about Oramed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oramed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (10.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oramed Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Oramed Pharmaceuticals Share Price Passes Below 200-Day Moving Average - Should You Sell - MarketBeat |
- Analyzing Oramed Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oramed Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Oramed Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oramed Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oramed Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oramed Pharmaceuticals' stock. These opinions can provide insight into Oramed Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.